How has the pharmaceutical industry and civil society responded?
The pharmaceutical industry has responded well to the challenges that COVID-19 has posed to people with diabetes. We published a report on the situation concerning diabetes medicines and supplies in the region, which industry very heavily contributed to. We found that although there were logistics problems caused by the lockdown measures, the supply chain has been generally maintained as a result of industry and governments acting cooperatively. They have also responded well to civil society and diabetes organisations, providing moral support, information and continuing to support our efforts to raise awareness of diabetes.
Diabetes associations and civil society have stepped up across Europe. We have had several conversations with diabetes associations, both professional and representing people with diabetes, across the region. They have been disseminating good information for people with diabetes, particularly across social media platforms. The digital age has finally arrived. It took a crisis to get us there but we’ve arrived in the digital age and engagement through social media platforms has been particularly good during this time.
What do you think will be the longer-term impact of the COVID-19 pandemic on people with diabetes and health professionals?
I think the long-term effect of COVID-19 on people with diabetes will be quite marked, particularly for people who have not been able to access care, such as those living with complications. As a result of people being afraid of going to the hospital to access healthcare, we are going to see people presenting late with complications affecting their eyes, feet, heart and kidneys. We are already seeing this in medical admission units across Europe. There is, however, a silver lining to these clouds, and that is that many more people will be able to access their care online or digitally.
For health professionals post-COVID, we’re going to see a different way of working and that different way of working is going to require a different kind of skill-set – digital multidisciplinary teamwork – because that’s what people are going to expect now. How we interact with patients digitally, particularly involving the multidisciplinary team is going to be important. COVID-19 has also shown, particularly in some of the Western European countries, how quickly roles have been repurposed to be used for efforts against that virus. If that can happen for COVID-19, I think roles can be repurposed and rescaled for diabetes care as well. We have been waiting for that for a long time, and I believe that for health professionals, this is going to involve a different way of working, as well as new roles and developments that can be fast-tracked to help deliver care for the future.
I feel that the role of the voice of the person with diabetes is going to get bigger after COVID-19 and rightly so. We need to facilitate that and make it happen. We do not want to lose the voice of the person with diabetes, particularly regarding the way that they want their care to be structured. Too often, we have not listened to the way that they want their care structured around them. This is a golden opportunity to make that happen properly for people with diabetes. People with diabetes are collaborating much more with each other on social media platforms, and that is only to be encouraged and paid attention to. Healthcare professionals should engage with that more.
Be the first to comment